173 related articles for article (PubMed ID: 2245488)
21. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors.
Mayer LD; Dougherty G; Harasym TO; Bally MB
J Pharmacol Exp Ther; 1997 Mar; 280(3):1406-14. PubMed ID: 9067330
[TBL] [Abstract][Full Text] [Related]
22. Liposomal encapsulation of 3'-azido-3'-deoxythymidine (AZT) results in decreased bone marrow toxicity and enhanced activity against murine AIDS-induced immunosuppression.
Phillips NC; Skamene E; Tsoukas C
J Acquir Immune Defic Syndr (1988); 1991; 4(10):959-66. PubMed ID: 1890605
[TBL] [Abstract][Full Text] [Related]
23. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia.
Mayer LD; Nayar R; Thies RL; Boman NL; Cullis PR; Bally MB
Cancer Chemother Pharmacol; 1993; 33(1):17-24. PubMed ID: 8269584
[TBL] [Abstract][Full Text] [Related]
24. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
25. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity of doxorubicin encapsulated in hexadecylphosphocholine (HePC) liposomes against human xenografts on Scid mice.
Papagiannaros A; Hatziantoniou S; Lelong-Rebel IH; Papaioannou GT; Dimas K; Demetzos C
In Vivo; 2006; 20(1):129-35. PubMed ID: 16433041
[TBL] [Abstract][Full Text] [Related]
27. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors.
Mayer LD; Bally MB; Loughrey H; Masin D; Cullis PR
Cancer Res; 1990 Feb; 50(3):575-9. PubMed ID: 2297698
[TBL] [Abstract][Full Text] [Related]
28. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients.
Mayer LD; Tai LC; Bally MB; Mitilenes GN; Ginsberg RS; Cullis PR
Biochim Biophys Acta; 1990 Jun; 1025(2):143-51. PubMed ID: 2364073
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin.
Balazsovits JA; Mayer LD; Bally MB; Cullis PR; McDonell M; Ginsberg RS; Falk RE
Cancer Chemother Pharmacol; 1989; 23(2):81-6. PubMed ID: 2491964
[TBL] [Abstract][Full Text] [Related]
30. An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin.
Tardi PG; Swartz EN; Harasym TO; Cullis PR; Bally MB
J Immunol Methods; 1997 Dec; 210(2):137-48. PubMed ID: 9520297
[TBL] [Abstract][Full Text] [Related]
31. Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes.
Rahman A; Carmichael D; Harris M; Roh JK
Cancer Res; 1986 May; 46(5):2295-9. PubMed ID: 3697976
[TBL] [Abstract][Full Text] [Related]
32. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation.
Herman EH; Rahman A; Ferrans VJ; Vick JA; Schein PS
Cancer Res; 1983 Nov; 43(11):5427-32. PubMed ID: 6616474
[TBL] [Abstract][Full Text] [Related]
33. A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines.
Papagiannaros A; Hatziantoniou S; Dimas K; Papaioannou GT; Demetzos C
Biomed Pharmacother; 2006 Jan; 60(1):36-42. PubMed ID: 16271845
[TBL] [Abstract][Full Text] [Related]
34. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).
Cowens JW; Creaven PJ; Greco WR; Brenner DE; Tung Y; Ostro M; Pilkiewicz F; Ginsberg R; Petrelli N
Cancer Res; 1993 Jun; 53(12):2796-802. PubMed ID: 8504422
[TBL] [Abstract][Full Text] [Related]
35. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models.
Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z
J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726
[TBL] [Abstract][Full Text] [Related]
36. Effects of fluidity and vesicle size on antitumor activity and myelosuppressive activity of liposomes loaded with daunorubicin.
Nagayasu A; Shimooka T; Kinouchi Y; Uchiyama K; Takeichi Y; Kiwada H
Biol Pharm Bull; 1994 Jul; 17(7):935-9. PubMed ID: 8000381
[TBL] [Abstract][Full Text] [Related]
37. Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation.
Webb MS; Boman NL; Wiseman DJ; Saxon D; Sutton K; Wong KF; Logan P; Hope MJ
Antimicrob Agents Chemother; 1998 Jan; 42(1):45-52. PubMed ID: 9449259
[TBL] [Abstract][Full Text] [Related]
38. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
Gabizon A; Martin F
Drugs; 1997; 54 Suppl 4():15-21. PubMed ID: 9361957
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times.
Gabizon A; Shiota R; Papahadjopoulos D
J Natl Cancer Inst; 1989 Oct; 81(19):1484-8. PubMed ID: 2778836
[TBL] [Abstract][Full Text] [Related]
40. Physical-chemistry characteristics and biodistribution of poly(ethylene glycol)-coated liposomes using poly(oxyethylene) cholesteryl ether.
Ishiwata H; Vertut-Doï A; Hirose T; Miyajima K
Chem Pharm Bull (Tokyo); 1995 Jun; 43(6):1005-11. PubMed ID: 7641302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
